<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00785863</url>
  </required_header>
  <id_info>
    <org_study_id>2008-000904-10</org_study_id>
    <nct_id>NCT00785863</nct_id>
  </id_info>
  <brief_title>Modulation of Remifentanil-induced Postinfusion Hyperalgesia</brief_title>
  <official_title>Modulation of Remifentanil-induced Analgesia and Postinfusion Hyperalgesia by Parecoxib or Ketorolac in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rikshospitalet University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In addition to alleviate pain there is growing evidence that Âµ-opioids enhance pain. This
      problem is known as opioid induced hyperalgesia(OIH).The NMDA receptor is involved in opioid
      induced hyperalgesia it may be possible to block OIH by cyclooxygenase inhibitors. This has
      been demonstrated with parecoxib, a COX-II inhibitor, in a experimental pain model.Both COX-1
      and COX-2 are expressed in the spinal cord. It would be of interest to investigate whether a
      COX-1 preferring inhibitor like ketorolac also can reduce opioid induced hyperalgesic in this
      experimental pain model.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Remifentanil is an fast acting opioid which has become very popular to use during surgery.

      There are studies, both experimental 1-3 and clinical 4;5, which indicate that remifentanil
      after end of infusion trigger enhanced pain experience and enhanced opioid consumption
      postoperatively.

      Therefore it is important to look at possibilities to block this enhanced pain experience
      (opioid induced hyperalgesia - OIH). Ketamin has demonstrated to block this effect 5;6
      through the NMDA receptor. Unfortunately ketamin has some seriously side-effects like
      hallucinations, and is therefore not suitable in ordenary clinical use.

      Recently, it has been demonstrated that parecoxib (a COX-2 inhibitor) can prevent
      remifentanil-induced postinfusion hyperalgesia in a study on healthy volunteers.7 COX-2
      inhibitors have some disadvantages because of the longterm adverse effects like cardiac
      arrest. Therefore it would be of interest to look at a COX-1 preferring NSAID, like
      ketorolac, to see if also non-selective NSAIDs can partly block remifentanil-induced
      postinfusion hyperalgesia.

      To investigate this and to provoke pain and secondary hyperalgesia we use an intradermal
      electrical pain model which is well established.1;7-9 Detailed description of this model look
      at reference 7. H0 : Parecoxib prevents remifentanil postinfusion secondary hyperalgesi.
      Ketorolac does not prevent remifentanil postinfusion secondary hyperalgesi HA : Parecoxib and
      ketorolac prevent remifentanil postinfusion secondary hyperalgesi.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>H0 : Parecoxib prevents remifentanil postinfusion secondary hyperalgesi. Ketorolac does not prevent remifentanil postinfusion secondary hyperalgesi.</measure>
    <time_frame>during the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HA : Parecoxib and ketorolac prevent remifentanil postinfusion secondary hyperalgesi.</measure>
    <time_frame>During the study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hyperalgesia, Secondary</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketorolac and remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Parecoxib and remifentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo IV before placebo infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
    <description>placebo IV and remifentanil infusion</description>
    <arm_group_label>Remifentanil</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketorolac and remifentanil</intervention_name>
    <description>Ketorolac IV and remifentanil infusion</description>
    <arm_group_label>Ketorolac and remifentanil</arm_group_label>
    <other_name>Toradol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Parecoxib and remifentanil</intervention_name>
    <description>Parecoxib IV and remifentanil infusion</description>
    <arm_group_label>Parecoxib and remifentanil</arm_group_label>
    <other_name>Dynastat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers

        Exclusion Criteria:

          -  Allergy to the drugs used in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Harald Lenz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Johan Raeder, Prof.,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Audun Stubhaug, Prof.,MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Rikshospitalet University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ullevaal University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0407</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 4, 2008</study_first_submitted>
  <study_first_submitted_qc>November 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2008</study_first_posted>
  <last_update_submitted>June 30, 2011</last_update_submitted>
  <last_update_submitted_qc>June 30, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Ullevaal University Hospital</name_title>
    <organization>Ullevaal University Hospital</organization>
  </responsible_party>
  <keyword>hyperalgesia</keyword>
  <keyword>remifentanil</keyword>
  <keyword>ketorolac</keyword>
  <keyword>parecoxib</keyword>
  <keyword>COX-1 inhibitor</keyword>
  <keyword>COX-2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Parecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

